May 30th 2023
Results of the study, published in the Journal of Clinical Investigation, showed evidence that an experimental drug called 32-134D may prevent or slow vision loss in people with diabetes.
Medical Crossfire®: Expert Perspectives in Geographic Atrophy – How Can We Prepare for a New Era of Treatment?
View More
Community Practice Connections™: Ophthalmology and Oncology Perspectives on Integrating Novel Bispecific Antibodies Into the Uveal Melanoma Treatment Paradigm
View More
Medical Crossfire®: Ophthalmology and Oncology Perspectives on Integrating Novel Bispecific Antibodies Into the Uveal Melanoma Treatment Paradigm
View More
Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations
View More
Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations
View More
(COPE Credit) Analyzing Novel Tear Stimulating Treatments for Special Populations in Dry Eye Disease
View More
(COPE Credit) Analyzing Novel Tear Stimulating Treatments for Special Populations in Dry Eye Disease
View More
(CME/CNE Credit) Analyzing Novel Tear Stimulating Treatments for Special Populations in Dry Eye Disease
View More
(CME/CNE Credit) Analyzing Novel Tear Stimulating Treatments for Special Populations in Dry Eye Disease
View More
(COPE Credit) Community Practice Connections™: Restoring the Surface – Impact of Preservatives and Novel Formulations in First Line Treatments for Dry Eye Disease
View More
(COPE Credit) Community Practice Connections™: Restoring the Surface – Impact of Preservatives and Novel Formulations in First Line Treatments for Dry Eye Disease
View More
(CME/CNE Credit) Community Practice Connections™: Restoring the Surface Impact of Preservatives and Novel Formulations in First Line Treatments for Dry Eye Disease
View More
(CME/CNE Credit) Community Practice Connections™: Restoring the Surface Impact of Preservatives and Novel Formulations in First Line Treatments for Dry Eye Disease
View More
(CME Credit) Community Practice Connections™: Improving Management of MGD-Associated Dry Eye Disease—A Look to the Future of Treatment
View More
(CME Credit) Community Practice Connections™: Improving Management of MGD-Associated Dry Eye Disease—A Look to the Future of Treatment
View More
(COPE Credit) Community Practice Connections™: Improving Management of MGD-Associated Dry Eye Disease—A Look to the Future of Treatment
View More
(COPE Credit) Community Practice Connections™: Improving Management of MGD-Associated Dry Eye Disease—A Look to the Future of Treatment
View More
C.R.U. Eye Symposium (Current, Relevant, Useful)
11/10/2023-11/12/2023
View More
C.R.U. Eye Symposium (Current, Relevant, Useful)
11/10/2023-11/12/2023
View More
Cases and Conversations™: New Treatment Strategies for nAMD & DME
07/28/2023
View More
Cases and Conversations™: New Treatment Strategies for nAMD & DME
07/28/2023
View More
Shared Perspectives in Managing Presbyopia – Understanding a New Paradigm for Optimizing Quality of Life
View More
Shared Perspectives in Managing Presbyopia – Understanding a New Paradigm for Optimizing Quality of Life
View More
Perfecting Co-Management of Glaucoma – Utilizing Development in the Spectrum of Treatment Options
View More
Perfecting Co-Management of Glaucoma – Utilizing Development in the Spectrum of Treatment Options
View More
Expert Insights in Geographic Atrophy with Transformative Care on the Horizon – Understanding the Complement System as a Target for Treatment
View More
Expert Insights in Geographic Atrophy with Transformative Care on the Horizon – Understanding the Complement System as a Target for Treatment
View More
(COPE Credit) Patient, Provider, and Caregiver Connection™: Individualizing Care in Allergic Conjunctivitis – Understanding the Patient’s Perspective in Alleviating Disease Burden
View More
(COPE Credit) Patient, Provider, and Caregiver Connection™: Individualizing Care in Allergic Conjunctivitis – Understanding the Patient’s Perspective in Alleviating Disease Burden
View More
(CME Credit) Patient, Provider, and Caregiver Connection™: Individualizing Care in Allergic Conjunctivitis – Understanding the Patient’s Perspective in Alleviating Disease Burden
View More
APAO 2023: Step therapy from Bevacizumab to Aflibercept for DME
February 24th 2023Voraporn Chaikitmongkol, MD, discussed step therapy and reported the results of a major study, the Diabetic Retinopathy Clinical Research (DRCR) Protocol AC, at the 38th Asia-Pacific Academy of Ophthalmology Congress, in Kuala Lumpur, Malaysia.
2023: What awaits ophthalmology in the year ahead
December 12th 2022As we approach the end of 2022, members of the Ophthalmology Times Europe® Editorial Advisory Board were asked to predict developments in their ophthalmic specialties and interests. A focus is our ageing population, while efficiency and productivity are also on their minds. The board members agree that one of the major challenges in the year to come will be the large number of patients awaiting diagnosis and treatment, which is only going to increase with the rising average life expectancy worldwide.
Sailing study and extension study: Superiority of conbercept over laser in DME
November 1st 2022The Sailing study was a 12-month, 18-center, randomized, double-masked, double-sham, parallel-controlled, phase 3 trial that was conducted in China and included eyes with center-involved DME that were randomly assigned to undergo either laser photocoagulation followed by as-needed sham intravitreal injections or sham laser photocoagulation followed by as-needed 0.5 mg intravitreal injections of conbercept.
Faricimab eradicates center-involved DME faster than aflibercept
October 2nd 2022The data analysis indicated that patients achieved robust visual gains and central subfield thickness reductions with faricimab dosed every 8 weeks and with PTI dosing up to every 16 weeks. The gains were sustained through year 2 of the trials.
European Commission approves faricimab for treatment of wet AMD, DME
September 19th 2022Roche’s treatment of faricimab is the first and only FDA-approved medicine targeting two distinct pathways, angiopoietin (Ang)-2 and vascular endothelial growth factor (VEGF)-A, that often cause retinal diseases that may cause visual loss.
PHOTON, PULSAR trials: Aflibercept meets primary endpoints in safety, efficacy
September 10th 2022Regeneron announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema and wet age-related macular degeneration.
First patient enrolled in Phase 2 study of D-4517.2 for treatment of wet AMD, DME
September 8th 2022The first stage of the study will evaluate the safety and relative pharmacodynamic effect of different doses of subcutaneously administered D-4517.2 compared to intravitreal injection of aflibercept, an approved therapy, in both wet AMD and DME patients up to 12 weeks.